Efficacy and safety of an Aron Alpha method in managing giant ovarian tumors
- PMID: 37033210
- PMCID: PMC10073634
- DOI: 10.1016/j.gore.2023.101167
Efficacy and safety of an Aron Alpha method in managing giant ovarian tumors
Abstract
Background: Giant malignant tumors have an increased risk of intraoperative rupture, which might lead to a worse disease condition and tumor recurrence. We performed a clinical study on patients with a giant ovarian mass who underwent laparoscopy combined with an Aron Alpha method.
Methods: This retrospective clinical study spanned from January 2016 to September 2022 and included 23 patients with giant ovarian tumors treated with an Aron Alpha method.
Results: The mean age of the subjects was 47.6 ± 17.8 years, mean tumor diameter 20.4 ± 5.8 cm, mean surgical duration 87.2 ± 33.1 min, and mean hemorrhage volume 94.1 ± 92.2 mL. No patient experienced intraoperative tumor rupture or surgery-related symptoms. Histopathology of excised samples revealed serous cyst adenoma and mucinous cystadenoma, mucinous cystadenoma of borderline malignancy and mature cystic teratoma, and endometriotic cyst adenoma in 6, 4, and 3 patients, respectively. The mean hospitalization period was 6.0 ± 1.2 days, and the hospitalization period was not extended in any subject.
Conclusion: The Aron Alpha method allows tumor resection without capsular rupture and is a useful, minimally invasive surgical method for resecting giant ovarian tumors in which malignancy cannot be ruled out.
Keywords: Aron Alpha method; Giant ovarian tumor; Laparoscopy; Malignant ovarian tumor; Mini-laparotomy; Minimally invasive surgery.
©2023PublishedbyElsevierInc.
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures

Similar articles
-
Management of Large Ovarian Tumors in Elderly Patients Using the Aron Alpha Method and Principles of Enhanced Recovery after Surgery.Gynecol Minim Invasive Ther. 2024 Sep 7;13(4):215-220. doi: 10.4103/gmit.gmit_77_23. eCollection 2024 Oct-Dec. Gynecol Minim Invasive Ther. 2024. PMID: 39660235 Free PMC article.
-
A Recurrent Mucinous Neoplasm Originating From an Ovarian Mucinous Cystadenoma After an Adnexectomy As the First Procedure: A Case Report.Cureus. 2022 Nov 8;14(11):e31258. doi: 10.7759/cureus.31258. eCollection 2022 Nov. Cureus. 2022. PMID: 36514617 Free PMC article.
-
Accuracy of intraoperative frozen section for the evaluation of ovarian neoplasms: an institutional experience.World J Surg Oncol. 2016 Mar 31;14:91. doi: 10.1186/s12957-016-0849-x. World J Surg Oncol. 2016. PMID: 27029917 Free PMC article.
-
Epithelial borderline ovarian tumor: Diagnosis and treatment strategy.Obstet Gynecol Sci. 2015 May;58(3):183-7. doi: 10.5468/ogs.2015.58.3.183. Epub 2015 May 19. Obstet Gynecol Sci. 2015. PMID: 26023666 Free PMC article. Review.
-
Magnetic resonance imaging findings of cystic ovarian tumors: major differential diagnoses in five types frequently encountered in daily clinical practice.Jpn J Radiol. 2022 Dec;40(12):1213-1234. doi: 10.1007/s11604-022-01321-x. Epub 2022 Aug 2. Jpn J Radiol. 2022. PMID: 35916971 Free PMC article. Review.
Cited by
-
Giant Mature Ovarian Cystic Teratoma in a Pediatric Patient: Case Report and Literature Review.Case Rep Oncol. 2023 Oct 6;16(1):1066-1072. doi: 10.1159/000534141. eCollection 2023 Jan-Dec. Case Rep Oncol. 2023. PMID: 37900852 Free PMC article.
-
Management of Large Ovarian Tumors in Elderly Patients Using the Aron Alpha Method and Principles of Enhanced Recovery after Surgery.Gynecol Minim Invasive Ther. 2024 Sep 7;13(4):215-220. doi: 10.4103/gmit.gmit_77_23. eCollection 2024 Oct-Dec. Gynecol Minim Invasive Ther. 2024. PMID: 39660235 Free PMC article.
References
LinkOut - more resources
Full Text Sources